Diligence Events. Company, whether itself, or through its Affiliates, Third Party sublicensees, contractors, or Third Parties funded by Company under a research or service agreement, will use commercially reasonable efforts to achieve each of the milestone diligence events by the applicable completion date listed in the table below for the first Licensed Product for human therapeutic or prophylactic use in Field of Use B. Company will provide Cellscript with written notice within [***] days of first completion of each milestone diligence event for a Licensed Product for human therapeutic or prophylactic use in Field of Use B by Company or an Affiliate or Third Party sublicensee. 1. [***] [***]
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the diligence events by the applicable completion date listed in the table below for the first Licensed Product. [**] [ **] [**] [ **] [**] [ **] [**] [ **] [**].
Diligence Events. Licensee, itself and/or through its Affiliates, Sublicensees or Third Party subcontractors, shall achieve each Diligence Event set forth in the table below by the corresponding Achievement Date (each a “Diligence Event”) for the first Product for each Licensed Indication. [***] Diligence Event for each Licensed Indication, on a Licensed Indication-by-Licensed Indication basis Achievement Date [***] [***]
Diligence Events. The Company will use Commercially Reasonable Efforts to achieve each of the diligence events by the applicable completion date listed in Appendix A. In addition to usual and reasonable terms for termination, the University reserves the right to terminate the Agreement if Company fails to achieve one or more diligence events on or before their respective achievement date.
Diligence Events. The Company will use commercially reasonable efforts (either itself or through its Affiliates or sublicensees) to achieve each of the diligence events set forth below by the applicable completion date listed in the table below for the first Licensed Product. For purposes of this Section 2.3 and Section 3.4 below, the diligence or milestone event, as the case may be, associated with the initiation of a Phase II clinical trial for a Licensed Product shall be deemed achieved upon the initiation of any Phase II portion of a Phase I trial for such Licensed Product. Filing of IND for the Licensed Product July 1, 2007 [**] [**] [**] [**] [**] [**] [**] [**]
Diligence Events. Company shall achieve each of the following Diligence Events by the corresponding Achievement Date for each Licensed Product: [*] [*] after DTP for such Licensed Product. [*] [*] after DTP for such Licensed Product. [*] [*] after DTP for such Licensed Product Penn acknowledges that the timeline for each Achievement Date is based on the assumption that development and commercialization of a Licensed Product does not encounter material regulatory or other delays for reasons outside of Licensee’s reasonable control. Where such circumstances exist, Penn agrees to negotiate in good faith with Licensee, upon Licensee’s written request and provided such request is made at least [*] prior to the Achievement Date for a Diligence Event, an extension of the Achievement Date for a Diligence Event for such Licensed Product as reasonably requested by Licensee. If the Parties have not agreed on a requested extension within [*] of such request, [*]. To the extent Licensee has achieved any Diligence Event by the corresponding Achievement Date in relation to a given Licensed Product for an Indication, Licensee will be deemed to have also met its diligence obligations under Section 5.6 with respect to such Licensed Product and its associated Indication(s) through the corresponding Achievement Date.
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the Diligence Events by the applicable completion date listed in the table below for the first Licensed Product: [***] as set forth in [***] [***] [***] after Effective Date Receipt of IND approval for a Licensed Product 4 years after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date [***] [***] after Effective Date provided that with respect to the foregoing completion dates, to the extent any delay in meeting such completion dates is due to bona fide unforeseen discovery or development obstacles, and while Company is diligently advancing the program, such completion dates will be extended upon mutual agreement of the parties, which agreement will not be unreasonably withheld.
Diligence Events. Licensee shall use [***] at its own cost and expense to develop a Licensed Product, to conduct all development necessary to obtain regulatory approval to market such Licensed Product, and to commercialize such Licensed Product, according to the applicable completion date listed in the table below for the Licensed Product.
Diligence Events. The Company will use commercially reasonable efforts (either itself or through its Affiliates or sublicensees) to achieve each of the diligence events set forth below by the applicable completion date listed in the table below for the first Licensed Product. For purposes of this Section 2.3 and Section 3.3 below, the diligence or milestone event, as the case may be, associated with the initiation of a Phase II clinical trial for a Licensed Product shall be deemed achieved upon the initiation of any Phase II portion of a Phase I trial for such Licensed Product.
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the diligence events by the applicable completion date listed in the table below for the first Licensed Product. Delivery of a completed initial Business Plan to the Licensor Parties in a form acceptable to the Licensor Parties January 20, 2013 First dosing of first patient in a Phase III or other pivotal clinical trial for first licensed product Fifteen (15) months from the Execution Date of the Agreement Filing of NDA for first Licensed Product Thirty Nine (39) months from the Execution Date of the Agreement First Sale of the first Licensed Product as covered by the NDA March of 2017 (unless the Company is able to fast track FDA approval with the orphan designation)
